{"id":"W4376613634","doi":"10.1016/j.esmoop.2023.101463","title":"124O Patritumab deruxtecan (HER3-DXd) in hormonal receptor-positive/HER2-negative (HR+/HER2-) and triple-negative breast cancer (TNBC): Results of part B of SOLTI TOT-HER3 window of opportunity trial","year":2023,"lang":"en","type":"article","venue":"ESMO Open","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Daiichi Sankyo Europe; Genentech; PharmaMar; Eisai; Clovis Oncology; Eli Lilly and Company; AstraZeneca; Les Laboratories Pierre Fabre; Seagen; Relay Therapeutics; Gilead Sciences; Veracyte; Pfizer; Oncolytics Biotech","keywords":"Medicine; Triple-negative breast cancer; Breast cancer; Internal medicine; Oncology; Clinical trial; Cancer; Gastroenterology","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000696387,0.000472696,0.0007939848,0.0002194833,0.0001500364,0.0005142106,0.0002498692,0.0003810463,0.001691674],"category_scores_gemma":[0.0003959755,0.0001611981,0.0005051765,0.0001990761,0.0003122667,0.0003047725,0.0002387339,0.0009713475,0.0003163546],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003553229,"about_ca_system_score_gemma":0.0004171372,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004907842,"about_ca_topic_score_gemma":0.00115881,"domain_scores_codex":[0.9997954,0.0001047127,0.00001212336,0.00001969096,0.00002737558,0.00004071096],"domain_scores_gemma":[0.999805,0.00004308144,0.00003917944,0.00001604701,0.00001048771,0.0000862055],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.6586586,0.02942109,0.01806111,0.0005706493,0.0008002105,0.0003819347,0.0002611702,0.001521532,0.07239592,0.0003219127,0.002364836,0.2152411],"study_design_scores_gemma":[0.2570436,0.660863,0.06465491,0.0000618968,0.0006270134,0.000777831,0.00009830746,0.00127568,0.008440816,0.0002670393,0.005859579,0.00003037339],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9977337,0.0009720637,0.00007979516,0.0000924905,0.0000237729,0.0001840563,0.0002580213,0.00001167282,0.0006444528],"genre_scores_gemma":[0.9948475,0.001347583,0.0003862058,0.0002850194,0.00008347324,0.0003572404,0.001119035,0.000008131187,0.001565807],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001691674,"threshold_uncertainty_score":0.005659223,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04569858955533936,"score_gpt":0.339689188929266,"score_spread":0.2939905993739267,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}